What impact can molnupiravir have on the treatment of SARS-CoV-2 infection?

Kayali, Fatima; Leung, Marco Shiu Tsun; Wong, Wilson; Morgan, Kara Pittendrigh; Harky, Amer

Kayali, Fatima; Leung, Marco Shiu Tsun; Wong, Wilson; Morgan, Kara Pittendrigh; Harky, Amer.

Kayali F; UCLan Medical School, University of Central Lancashire, Preston, UK.
Leung MST; The Hillingdon Hospitals Foundation Trust, Uxbridge, UK.
Wong W; Imperial College Healthcare NHS Trust, London, UK.
Morgan KP; Ealing Hospital, London North West University Healthcare NHS Trust, Southall, UK.
Harky A; Department of Cardiology, Manchester Royal Infirmary, Manchester, UK.

Expert Opin Pharmacother ; 23(8): 865-868, 2022 06.

Article in English | MEDLINE | ID: covidwho-1764381

Subject(s)

COVID-19 Drug Treatment; Antiviral Agents/therapeutic use; Cytidine/analogs & derivatives; Humans; Hydroxylamines; SARS-CoV-2

Keywords

Antivirals; COVID-19; SARS-CoV-2; coronavirus; molnupiravir; pharmacotherapy

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Experimental Studies Limits: Humans Language: English Journal: Expert Opin Pharmacother Journal subject: Pharmacology Year: 2022 Document Type: Article Affiliation country: 14656566.2022.2057795

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google